메뉴 건너뛰기




Volumn 86, Issue 4, 2007, Pages 306-314

Treatment options in advanced myelodysplastic syndrome, with emphasis on epigenetic therapy

Author keywords

DNA methylation; Epigenetic therapy; Histone deacetylase inhibitors; Hypomethylation; Myelodysplastic syndrome

Indexed keywords

4 N ACETYLDINALINE; 4 PHENYLBUTYRIC ACID; 5 AZA 2' DEOXYCYTIDINE; 5,6 DIHYDROAZACITIDINE; AMSACRINE; ANTHRACYCLINE; APICIDIN; AZACITIDINE; CYCLOPHOSPHAMIDE; CYTARABINE; DEOXYCYTIDINE; DEPSIPEPTIDE; DNA; DNA METHYLTRANSFERASE INHIBITOR; ETOPOSIDE; FAZARABINE; FLUDARABINE; HISTONE; HISTONE DEACETYLASE INHIBITOR; IDARUBICIN; N (2 AMINOPHENYL) 4 (3 PYRIDINYLMETHOXYCARBONYLAMINOMETHYL)BENZAMIDE; OXAMFLATIN; TETRAPEPTIDE; TOPOTECAN; TRAPOXIN A; TRICHOSTATIN A; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID; VORINOSTAT; ZEBULARINE; DNA METHYLTRANSFERASE; HISTONE DEACETYLASE;

EID: 40449094573     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1532/IJH97.07034     Document Type: Review
Times cited : (15)

References (105)
  • 1
    • 0034614637 scopus 로고    scopus 로고
    • The hallmarks of cancer
    • D Hanahan RA Weinberg 2000 The hallmarks of cancer Cell 100 57 70
    • (2000) Cell , vol.100 , pp. 57-70
    • Hanahan, D.1    Weinberg, R.A.2
  • 2
    • 0036274359 scopus 로고    scopus 로고
    • The fundamental role of epigenetic events in cancer
    • PA Jones SB Baylin 2002 The fundamental role of epigenetic events in cancer Nat Rev Genet 3 415 428
    • (2002) Nat Rev Genet , vol.3 , pp. 415-428
    • Jones, P.A.1    Baylin, S.B.2
  • 3
    • 0036144048 scopus 로고    scopus 로고
    • DNA methylation patterns and epigenetic memory
    • A Bird 2002 DNA methylation patterns and epigenetic memory Genes Dev 16 6 21
    • (2002) Genes Dev , vol.16 , pp. 6-21
    • Bird, A.1
  • 4
    • 0034610814 scopus 로고    scopus 로고
    • The language of covalent histone modifications
    • BD Strahl CD Allis 2000 The language of covalent histone modifications Nature 403 41 45
    • (2000) Nature , vol.403 , pp. 41-45
    • Strahl, B.D.1    Allis, C.D.2
  • 5
    • 0035839136 scopus 로고    scopus 로고
    • Translating the histone code
    • T Jenuwein CD Allis 2001 Translating the histone code Science 293 1074 1080
    • (2001) Science , vol.293 , pp. 1074-1080
    • Jenuwein, T.1    Allis, C.D.2
  • 6
    • 21244467166 scopus 로고    scopus 로고
    • Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies
    • KN Bhalla 2005 Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies J Clin Oncol 23 3971 3993
    • (2005) J Clin Oncol , vol.23 , pp. 3971-3993
    • Bhalla, K.N.1
  • 7
    • 0242624636 scopus 로고    scopus 로고
    • Epigenetic targets in hematopoietic malignancies
    • R Claus M Lubbert 2003 Epigenetic targets in hematopoietic malignancies Oncogene 22 6489 6496
    • (2003) Oncogene , vol.22 , pp. 6489-6496
    • Claus, R.1    Lubbert, M.2
  • 8
    • 0030897009 scopus 로고    scopus 로고
    • International scoring system for evaluating prognosis in myelodysplastic syndromes
    • P Greenberg C Cox MM LeBeau 1997 International scoring system for evaluating prognosis in myelodysplastic syndromes Blood 89 2079 2088
    • (1997) Blood , vol.89 , pp. 2079-2088
    • Greenberg, P.1    Cox, C.2    Lebeau, M.M.3
  • 9
    • 0345357773 scopus 로고    scopus 로고
    • Gene silencing in cancer in association with promoter hypermethylation
    • JG Herman SB Baylin 2003 Gene silencing in cancer in association with promoter hypermethylation N Engl J Med 349 2042 2054
    • (2003) N Engl J Med , vol.349 , pp. 2042-2054
    • Herman, J.G.1    Baylin, S.B.2
  • 10
    • 0035962631 scopus 로고    scopus 로고
    • DNA methylation, methyltransferases, and cancer
    • KD Robertson 2001 DNA methylation, methyltransferases, and cancer Oncogene 20 3139 3155
    • (2001) Oncogene , vol.20 , pp. 3139-3155
    • Robertson, K.D.1
  • 11
    • 0036733675 scopus 로고    scopus 로고
    • Chromatin modification and epigenetic reprogramming in mammalian development
    • E Li 2002 Chromatin modification and epigenetic reprogramming in mammalian development Nat Rev Genet 3 662 673
    • (2002) Nat Rev Genet , vol.3 , pp. 662-673
    • Li, E.1
  • 12
    • 0032574977 scopus 로고    scopus 로고
    • Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex
    • X Nan HH Ng CA Johnson 1998 Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex Nature 393 386 389
    • (1998) Nature , vol.393 , pp. 386-389
    • Nan, X.1    Ng, H.H.2    Johnson, C.A.3
  • 13
    • 0141502199 scopus 로고    scopus 로고
    • INK4B is common, is associated with deletion of genes on chromosome arm 7q and predicts a poor prognosis in therapy-related myelodysplasia and acute myeloid leukemia
    • INK4B is common, is associated with deletion of genes on chromosome arm 7q and predicts a poor prognosis in therapy-related myelodysplasia and acute myeloid leukemia Leukemia 17 1813 1819
    • (2003) Leukemia , vol.17 , pp. 1813-1819
    • Christiansen, D.H.1    Andersen, M.K.2    Pedersen-Bjergaard, J.3
  • 14
    • 0033179375 scopus 로고    scopus 로고
    • Concurrent DNA hypermethylation of multiple genes in acute myeloid leukemia
    • JR Melki PC Vincent SJ Clark 1999 Concurrent DNA hypermethylation of multiple genes in acute myeloid leukemia Cancer Res 59 3730 3740
    • (1999) Cancer Res , vol.59 , pp. 3730-3740
    • Melki, J.R.1    Vincent, P.C.2    Clark, S.J.3
  • 15
    • 10744233452 scopus 로고    scopus 로고
    • Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in hematopoietic malignancies
    • JP Issa G Garcia-Manero FJ Giles 2004 Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in hematopoietic malignancies Blood 103 1635 1640
    • (2004) Blood , vol.103 , pp. 1635-1640
    • Issa, J.P.1    Garcia-Manero, G.2    Giles, F.J.3
  • 17
    • 0942276838 scopus 로고    scopus 로고
    • Aberrant methylation of DAP-kinase in therapy-related acute myeloid leukemia and myelodysplastic syndromes
    • MT Voso A Scardocci F Guidi 2004 Aberrant methylation of DAP-kinase in therapy-related acute myeloid leukemia and myelodysplastic syndromes Blood 103 698 700
    • (2004) Blood , vol.103 , pp. 698-700
    • Voso, M.T.1    Scardocci, A.2    Guidi, F.3
  • 18
    • 24944476696 scopus 로고    scopus 로고
    • Hypermethylation of the suppressor of cytokine signalling-1(SOCS-1) in myelodysplastic syndrome
    • K Brakensiek F Länger B Schlegelberger H Kreipe U Lehmann 2005 Hypermethylation of the suppressor of cytokine signalling-1(SOCS-1) in myelodysplastic syndrome Br J Haematol 130 209 217
    • (2005) Br J Haematol , vol.130 , pp. 209-217
    • Brakensiek, K.1    Länger, F.2    Schlegelberger, B.3    Kreipe, H.4    Lehmann, U.5
  • 19
    • 17144366936 scopus 로고    scopus 로고
    • Aberrant methylation of the negative regulators RASSFIA, SHP-1 and SOCS-1 in myelodysplastic syndromes and acute myeloid leukaemia
    • MF Johan DT Bowen ME Frew AC Goodeve JT Reilly 2005 Aberrant methylation of the negative regulators RASSFIA, SHP-1 and SOCS-1 in myelodysplastic syndromes and acute myeloid leukaemia Br J Haematol 129 60 65
    • (2005) Br J Haematol , vol.129 , pp. 60-65
    • Johan, M.F.1    Bowen, D.T.2    Frew, M.E.3    Goodeve, A.C.4    Reilly, J.T.5
  • 20
    • 33744924582 scopus 로고    scopus 로고
    • CpG island methylation is a poor prognostic factor in myelodysplastic syndrome patients and is reversed by decitabine therapy: Results of a phase III randomized study
    • [abstract]. Abstract 790.
    • Shen L, Kantarjian H, Saba H, et al. CpG island methylation is a poor prognostic factor in myelodysplastic syndrome patients and is reversed by decitabine therapy: results of a phase III randomized study [abstract]. Blood 2005;106. Abstract 790.
    • (2005) Blood , vol.106
    • Shen, L.1    Kantarjian, H.2    Saba, H.3
  • 21
  • 22
    • 0015511621 scopus 로고
    • Prolongation of the lag period preceding the enhancement of thymidine and thymidylate kinase activity in regenerating rat liver by 5-azacytidine
    • A Cihák J Vesely 1972 Prolongation of the lag period preceding the enhancement of thymidine and thymidylate kinase activity in regenerating rat liver by 5-azacytidine Biochem Pharmacol 21 3257 3265
    • (1972) Biochem Pharmacol , vol.21 , pp. 3257-3265
    • Cihák, A.1    Vesely, J.2
  • 23
    • 0022244733 scopus 로고
    • Azapyrimidine nucleosides: Metabolism and inhibitory mechanisms
    • ák A Cih J Vesely J Skoda 1985 Azapyrimidine nucleosides: metabolism and inhibitory mechanisms Adv Enzyme Regul 24 335 354
    • (1985) Adv Enzyme Regul , vol.24 , pp. 335-354
    • Cih, Á.A.1    Vesely, J.2    Skoda, J.3
  • 25
    • 0020032366 scopus 로고
    • Inhibition of DNA methyltrans-ferase and induction of Friend erythroleukemia cell differentiation by 5-azacytidine and 5-aza-2′- deoxycytidine
    • F Creusot G Acs JK Christman 1982 Inhibition of DNA methyltrans-ferase and induction of Friend erythroleukemia cell differentiation by 5-azacytidine and 5-aza-2′-deoxycytidine J Biol Chem 257 2041 2048
    • (1982) J Biol Chem , vol.257 , pp. 2041-2048
    • Creusot, F.1    Acs, G.2    Christman, J.K.3
  • 26
    • 0014871518 scopus 로고
    • Phase specificity of 5-azacytidine against mammalian cells in tissue culture
    • LH Li EJ Olin TJ Fraser BK Bhuyan 1970 Phase specificity of 5-azacytidine against mammalian cells in tissue culture Cancer Res 30 2770 2775
    • (1970) Cancer Res , vol.30 , pp. 2770-2775
    • Li, L.H.1    Olin, E.J.2    Fraser, T.J.3    Bhuyan, B.K.4
  • 27
    • 0014872738 scopus 로고
    • Cytotoxicity and mode of action of 5-azacytidine on L1210 leukemia
    • LH Li EJ Olin HH Buskirk LM Reineke 1970 Cytotoxicity and mode of action of 5-azacytidine on L1210 leukemia Cancer Res 30 2760 2769
    • (1970) Cancer Res , vol.30 , pp. 2760-2769
    • Li, L.H.1    Olin, E.J.2    Buskirk, H.H.3    Reineke, L.M.4
  • 28
    • 0037068379 scopus 로고    scopus 로고
    • 5-Azacytidine and 5-aza-2′-deoxycytidine as inhibitors of DNA methylation: Mechanistic studies and their implications for cancer therapy
    • JK Christman 2002 5-Azacytidine and 5-aza-2′-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy Oncogene 21 5483 5495
    • (2002) Oncogene , vol.21 , pp. 5483-5495
    • Christman, J.K.1
  • 29
    • 0018860957 scopus 로고
    • Cellular differentiation, cytidine analogs and DNA methylation
    • PA Jones SM Taylor 1980 Cellular differentiation, cytidine analogs and DNA methylation Cell 20 85 93
    • (1980) Cell , vol.20 , pp. 85-93
    • Jones, P.A.1    Taylor, S.M.2
  • 30
    • 0035988868 scopus 로고    scopus 로고
    • Review of the clinical experience with 5-azacytidine and 5-aza-2′-deoxycytidine in solid tumors
    • A Aparicio JS Weber 2002 Review of the clinical experience with 5-azacytidine and 5-aza-2′-deoxycytidine in solid tumors Curr Opin Investig Drugs 3 627 633
    • (2002) Curr Opin Investig Drugs , vol.3 , pp. 627-633
    • Aparicio, A.1    Weber, J.S.2
  • 31
    • 0022303520 scopus 로고
    • Clinical trial on 5-aza-2′-deoxycytidine in patients with acute leukemia
    • RL Momparler GE Rivard M Gyger 1985 Clinical trial on 5-aza-2′-deoxycytidine in patients with acute leukemia Pharmacol Ther 30 277 286
    • (1985) Pharmacol Ther , vol.30 , pp. 277-286
    • Momparler, R.L.1    Rivard, G.E.2    Gyger, M.3
  • 32
    • 0019857236 scopus 로고
    • Phase I study on 5-aza-2′-deoxycytidine in children with acute leukemia
    • GE Rivard RL Momparler J Demers 1981 Phase I study on 5-aza-2′-deoxycytidine in children with acute leukemia Leuk Res 5 453 462
    • (1981) Leuk Res , vol.5 , pp. 453-462
    • Rivard, G.E.1    Momparler, R.L.2    Demers, J.3
  • 33
    • 0027309013 scopus 로고
    • Pilot study of 5-aza-2-deoxycytidine (decitabine) in the treatment of poor prognosis acute myelogenous leukemia patients: Preliminary results
    • MC Petti F Mandelli V Zagonel 1993;7(Supp Pilot study of 5-aza-2-deoxycytidine (decitabine) in the treatment of poor prognosis acute myelogenous leukemia patients: preliminary results Leukemia 1) 36 41
    • (1993) Leukemia , vol.1 , pp. 36-41
    • Petti, M.C.1    Mandelli, F.2    Zagonel, V.3
  • 34
    • 0030985020 scopus 로고    scopus 로고
    • Decitabine studies in chronic and acute myelogenous leukemia
    • HM Kantarjian SM O'Brien E Estey 1997;11(Supp Decitabine studies in chronic and acute myelogenous leukemia Leukemia 1) S35 S36
    • (1997) Leukemia , vol.1
    • Kantarjian, H.M.1    O'Brien, S.M.2    Estey, E.3
  • 35
    • 0030965033 scopus 로고    scopus 로고
    • A randomized phase II study on the effects of 5-aza-2-deoxycytidine combined with either amsacrine or idarubicin in patients with relapsed acute leukemia: An EORTC Leukemia Cooperative Group phase II study (06893)
    • R Willemze S Suciu E Archimbaud 1997;11(Supp A randomized phase II study on the effects of 5-aza-2-deoxycytidine combined with either amsacrine or idarubicin in patients with relapsed acute leukemia: an EORTC Leukemia Cooperative Group phase II study (06893) Leukemia 1) S24 S27
    • (1997) Leukemia , vol.1
    • Willemze, R.1    Suciu, S.2    Archimbaud, E.3
  • 36
    • 0027221806 scopus 로고
    • 5-Aza-2-deoxycytidine (decitabine) induces trilineage response in unfavourable myelodysplastic syndromes
    • V Zagonel Re G Lo G Marotta 1993;7(Supp 5-Aza-2-deoxycytidine (decitabine) induces trilineage response in unfavourable myelodysplastic syndromes Leukemia 1) 30 35
    • (1993) Leukemia , vol.1 , pp. 30-35
    • Zagonel, V.1    Lo Re, G.2    Marotta, G.3
  • 37
    • 0031042482 scopus 로고    scopus 로고
    • Continuous infusion of low-dose 5-aza-2′-deoxycytidine in elderly patients with high-risk myelodysplastic syndrome
    • PW Wijermans JW Krulder PC Huijgens P Neve 1997 Continuous infusion of low-dose 5-aza-2′-deoxycytidine in elderly patients with high-risk myelodysplastic syndrome Leukemia 11 1 5
    • (1997) Leukemia , vol.11 , pp. 1-5
    • Wijermans, P.W.1    Krulder, J.W.2    Huijgens, P.C.3    Neve, P.4
  • 38
    • 17444452612 scopus 로고    scopus 로고
    • Low-dose 5-aza-2′-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: A multicenter phase II study in elderly patients
    • P Wijermans M Lubbert G Verhoef 2000 Low-dose 5-aza-2′- deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients J Clin Oncol 18 956 962
    • (2000) J Clin Oncol , vol.18 , pp. 956-962
    • Wijermans, P.1    Lubbert, M.2    Verhoef, G.3
  • 39
    • 33646071894 scopus 로고    scopus 로고
    • Decitabine improves patient outcomes in myelodysplastic syndromes: Results of a phase III randomized study
    • H Kantarjian JP Issa CS Rosenfeld 2006 Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study Cancer 106 1794 1803
    • (2006) Cancer , vol.106 , pp. 1794-1803
    • Kantarjian, H.1    Issa, J.P.2    Rosenfeld, C.S.3
  • 40
    • 33846011361 scopus 로고    scopus 로고
    • Results of a randomized study of three schedules of low-dose decitabine in higher risk myelodysplastic syndrome and chronic myelomonocytic leukemia
    • H Kantarjian Y Oki G Garcia-Manero 2007 Results of a randomized study of three schedules of low-dose decitabine in higher risk myelodysplastic syndrome and chronic myelomonocytic leukemia Blood 109 52 57
    • (2007) Blood , vol.109 , pp. 52-57
    • Kantarjian, H.1    Oki, Y.2    Garcia-Manero, G.3
  • 41
    • 33745968917 scopus 로고    scopus 로고
    • Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia
    • BD Cheson PL Greenberg JM Bennett 2006 Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia Blood 108 419 425
    • (2006) Blood , vol.108 , pp. 419-425
    • Cheson, B.D.1    Greenberg, P.L.2    Bennett, J.M.3
  • 42
    • 0017249671 scopus 로고
    • A phase I study of 5-azacytidine (NSC-102816)
    • BI Shnider M Baig J Colsky 1976 A phase I study of 5-azacytidine (NSC-102816) J Clin Pharmacol 16 205 212
    • (1976) J Clin Pharmacol , vol.16 , pp. 205-212
    • Shnider, B.I.1    Baig, M.2    Colsky, J.3
  • 43
    • 0017136745 scopus 로고
    • A comparative clinical trial of 5-azacytidine and guanazole in previously treated adults with acute nonlympho-cytic leukemia
    • JA Levi PH Wiernik 1976 A comparative clinical trial of 5-azacytidine and guanazole in previously treated adults with acute nonlympho-cytic leukemia Cancer 38 36 41
    • (1976) Cancer , vol.38 , pp. 36-41
    • Levi, J.A.1    Wiernik, P.H.2
  • 44
    • 0021258302 scopus 로고
    • A randomized comparison of postremission therapy in acute myelogenous leukemia: A Southeastern Cancer Study Group trial
    • WR Vogler EF Winton DS Gordon MR Raney B Go L Meyer 1984 A randomized comparison of postremission therapy in acute myelogenous leukemia: a Southeastern Cancer Study Group trial Blood 63 1039 1045
    • (1984) Blood , vol.63 , pp. 1039-1045
    • Vogler, W.R.1    Winton, E.F.2    Gordon, D.S.3    Raney, M.R.4    Go, B.5    Meyer, L.6
  • 47
    • 0017082530 scopus 로고
    • 5-Azacytidine: A new anti-cancer drug with effectiveness in acute myelogenous leukemia
    • DD Von Hoff M Slavik FM Muggia 1976 5-Azacytidine: a new anti-cancer drug with effectiveness in acute myelogenous leukemia Ann Intern Med 85 237 245
    • (1976) Ann Intern Med , vol.85 , pp. 237-245
    • Von Hoff, D.D.1    Slavik, M.2    Muggia, F.M.3
  • 48
    • 0025825531 scopus 로고
    • Toxicity trials of amsacrine (AMSA) and etopo-side +/- azacitidine (AZ) in childhood acute non-lymphocytic leukemia (ANLL): A pilot study
    • CP Steuber T Holbrook B Camitta VJ Land C Sexauer J Krischer 1991 Toxicity trials of amsacrine (AMSA) and etopo-side +/- azacitidine (AZ) in childhood acute non-lymphocytic leukemia (ANLL): a pilot study Invest New Drugs 9 181 184
    • (1991) Invest New Drugs , vol.9 , pp. 181-184
    • Steuber, C.P.1    Holbrook, T.2    Camitta, B.3    Land, V.J.4    Sexauer, C.5    Krischer, J.6
  • 49
    • 0020466344 scopus 로고
    • 5-azacytidine selectively increases gamma-globin synthesis in a patient with beta+ tha-lassemia
    • TJ Ley J DeSimone NP Anagnou 1982 5-azacytidine selectively increases gamma-globin synthesis in a patient with beta+ tha-lassemia N EnglJ Med 307 1469 1475
    • (1982) N EnglJ Med , vol.307 , pp. 1469-1475
    • Ley, T.J.1    Desimone, J.2    Anagnou, N.P.3
  • 50
    • 0004959517 scopus 로고
    • Treatment of sickle cell anemia with 5-azacytidine results in increased fetal hemoglobin production and is associated with non-random hypomethylation of DNA around the ã-ä-β-globin gene complex
    • S Charache G Dover K Smith CC Talbot M Moyer S Boyer 1983 Treatment of sickle cell anemia with 5-azacytidine results in increased fetal hemoglobin production and is associated with non-random hypomethylation of DNA around the ã-ä-β-globin gene complex Proc NatlAcad Sci USA 80 4842 4846
    • (1983) Proc NatlAcad Sci USA , vol.80 , pp. 4842-4846
    • Charache, S.1    Dover, G.2    Smith, K.3    Talbot, C.C.4    Moyer, M.5    Boyer, S.6
  • 51
    • 0027154222 scopus 로고
    • Effects of treatment with 5-azacytidine on the in vivo and in vitro hematopoiesis in patients with myelodysplastic syndromes
    • LR Silverman JF Holland RS Weinberg 1993;7(Supp Effects of treatment with 5-azacytidine on the in vivo and in vitro hematopoiesis in patients with myelodysplastic syndromes Leukemia 1) 21 29
    • (1993) Leukemia , vol.1 , pp. 21-29
    • Silverman, L.R.1    Holland, J.F.2    Weinberg, R.S.3
  • 52
    • 0037093195 scopus 로고    scopus 로고
    • Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: A study of the Cancer and Leukemia GroupB
    • LR Silverman EP Demakos BL Peterson 2002 Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the Cancer and Leukemia GroupB J Clin Oncol 20 2429 2440
    • (2002) J Clin Oncol , vol.20 , pp. 2429-2440
    • Silverman, L.R.1    Demakos, E.P.2    Peterson, B.L.3
  • 53
    • 21044439177 scopus 로고    scopus 로고
    • Approval summary: Azacitidine for treatment of myelodysplastic syndrome subtypes
    • E Kaminskas A Farrell S Abraham 2005 Approval summary: azacitidine for treatment of myelodysplastic syndrome subtypes Clin Cancer Res 11 3604 3608
    • (2005) Clin Cancer Res , vol.11 , pp. 3604-3608
    • Kaminskas, E.1    Farrell, A.2    Abraham, S.3
  • 54
    • 33748474416 scopus 로고    scopus 로고
    • Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: Studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B
    • LR Silverman DR McKenzie BL Peterson 2006 Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B J Clin Oncol 24 3895 3903
    • (2006) J Clin Oncol , vol.24 , pp. 3895-3903
    • Silverman, L.R.1    McKenzie, D.R.2    Peterson, B.L.3
  • 55
    • 38849152987 scopus 로고    scopus 로고
    • Decitabine induces responses in patients with myelodysplastic syndrome (MDS) after failure of azacitidine therapy
    • [abstract]. Abstract 518.
    • Borthakur G, Ravandi-Kashani F, Cortes J, et al. Decitabine induces responses in patients with myelodysplastic syndrome (MDS) after failure of azacitidine therapy [abstract].Blood 2006;108. Abstract 518.
    • (2006) Blood , vol.108
    • Borthakur, G.1    Ravandi-Kashani, F.2    Cortes, J.3
  • 56
    • 0037108309 scopus 로고    scopus 로고
    • Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-aza-2′-deoxycytidine (decitabine) treatment
    • M Daskalakis TT Nguyen C Nguyen 2002 Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-aza-2′- deoxycytidine (decitabine) treatment Blood 100 2957 2964
    • (2002) Blood , vol.100 , pp. 2957-2964
    • Daskalakis, M.1    Nguyen, T.T.2    Nguyen, C.3
  • 57
    • 33745714230 scopus 로고    scopus 로고
    • Combined DNA methyltrans-ferase and histone deacetylase inhibition in the treatment of myeloid neoplasms
    • SD Gore S Baylin E Sugar 2006 Combined DNA methyltrans-ferase and histone deacetylase inhibition in the treatment of myeloid neoplasms Cancer Res 66 6361 6369
    • (2006) Cancer Res , vol.66 , pp. 6361-6369
    • Gore, S.D.1    Baylin, S.2    Sugar, E.3
  • 58
    • 57849105832 scopus 로고    scopus 로고
    • Hypomethylation induction and molecular response after decitabine therapy in chronic myelomonocytic leukemia (CMML)
    • [abstract]. Abstract 2322.
    • Oki Y, Jelinek J, Kantarjian H, Issa JP. Hypomethylation induction and molecular response after decitabine therapy in chronic myelomonocytic leukemia (CMML) [abstract].Blood 2006;108. Abstract 2322.
    • (2006) Blood , vol.108
    • Oki, Y.1    Jelinek, J.2    Kantarjian, H.3    Issa, J.P.4
  • 59
    • 0036861629 scopus 로고    scopus 로고
    • DNA methyltransferase inhibitors: State of the art
    • J Goffin E Eisenhauer 2002 DNA methyltransferase inhibitors: state of the art Ann Oncol 13 1699 1716
    • (2002) Ann Oncol , vol.13 , pp. 1699-1716
    • Goffin, J.1    Eisenhauer, E.2
  • 60
    • 0032842834 scopus 로고    scopus 로고
    • Phase I study of arabinosyl-5-azacytidine (fazarabine) in adult acute leukemia and chronic myelogenous leukemia in blastic phase
    • M Wilhelm S O'Brien MB Rios 1999 Phase I study of arabinosyl-5- azacytidine (fazarabine) in adult acute leukemia and chronic myelogenous leukemia in blastic phase Leuk Lymphoma 34 511 518
    • (1999) Leuk Lymphoma , vol.34 , pp. 511-518
    • Wilhelm, M.1    O'Brien, S.2    Rios, M.B.3
  • 61
    • 0036965821 scopus 로고    scopus 로고
    • Zebularine: A novel DNA methylation inhibitor that forms a covalent complex with DNA methyltransferases
    • L Zhou X Cheng BA Connolly MJ Dickman PJ Hurd DP Hornby 2002 Zebularine: a novel DNA methylation inhibitor that forms a covalent complex with DNA methyltransferases J Mol Biol 321 591 599
    • (2002) J Mol Biol , vol.321 , pp. 591-599
    • Zhou, L.1    Cheng, X.2    Connolly, B.A.3    Dickman, M.J.4    Hurd, P.J.5    Hornby, D.P.6
  • 62
    • 10644256532 scopus 로고    scopus 로고
    • Zebularine: A new drug for epigenetic therapy
    • CB Yoo JC Cheng PA Jones 2004 Zebularine: a new drug for epigenetic therapy Biochem Soc Trans 32 910 912
    • (2004) Biochem Soc Trans , vol.32 , pp. 910-912
    • Yoo, C.B.1    Cheng, J.C.2    Jones, P.A.3
  • 63
    • 0030797585 scopus 로고    scopus 로고
    • Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain
    • W Gu RG Roeder 1997 Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain Cell 90 595 606
    • (1997) Cell , vol.90 , pp. 595-606
    • Gu, W.1    Roeder, R.G.2
  • 64
    • 0346688568 scopus 로고    scopus 로고
    • Altered interaction of HDAC5 with GATA-1 during MEL cell differentiation
    • K Watamoto M Towatari Y Ozawa 2003 Altered interaction of HDAC5 with GATA-1 during MEL cell differentiation Oncogene 22 9176 9184
    • (2003) Oncogene , vol.22 , pp. 9176-9184
    • Watamoto, K.1    Towatari, M.2    Ozawa, Y.3
  • 66
    • 0032760819 scopus 로고    scopus 로고
    • Leukemogenesis by CBF oncoproteins
    • AD Friedman 1999 Leukemogenesis by CBF oncoproteins Leukemia 13 1932 1942
    • (1999) Leukemia , vol.13 , pp. 1932-1942
    • Friedman, A.D.1
  • 67
    • 33646002067 scopus 로고    scopus 로고
    • Chemistry and biology of chromatin remodeling agents: State of art and future perspectives of HDAC inhibitors
    • M Rodriquez M Aquino I Bruno Martino G De M Taddei L Gomez-Paloma 2006 Chemistry and biology of chromatin remodeling agents: state of art and future perspectives of HDAC inhibitors Curr Med Chem 13 1119 1139
    • (2006) Curr Med Chem , vol.13 , pp. 1119-1139
    • Rodriquez, M.1    Aquino, M.2    Bruno, I.3    De Martino, G.4    Taddei, M.5    Gomez-Paloma, L.6
  • 68
    • 17744416444 scopus 로고    scopus 로고
    • Histone deacetylase inhibitor activates the WAF1/Cip1 gene promoter through the Sp1 sites
    • Y Sowa T Orita S Minamikawa 1997 Histone deacetylase inhibitor activates the WAF1/Cip1 gene promoter through the Sp1 sites Biochem Biophys Res Commun 241 142 150
    • (1997) Biochem Biophys Res Commun , vol.241 , pp. 142-150
    • Sowa, Y.1    Orita, T.2    Minamikawa, S.3
  • 69
    • 33644883611 scopus 로고    scopus 로고
    • Histone deacetylase inhibitor apicidin induces cyclin e expression through Sp1 sites
    • S Kim JK Kang YK Kim 2006 Histone deacetylase inhibitor apicidin induces cyclin E expression through Sp1 sites Biochem Biophys Res Commun 342 1168 1173
    • (2006) Biochem Biophys Res Commun , vol.342 , pp. 1168-1173
    • Kim, S.1    Kang, J.K.2    Kim, Y.K.3
  • 70
    • 9744223645 scopus 로고    scopus 로고
    • Histone deacetylase inhibitor trichostatin a represses estrogen receptor β-dependent transcription and promotes proteasomal degradation of cyclin D1 in human breast carcinoma cell lines
    • JP Alao EW Lam S Ali 2004 Histone deacetylase inhibitor trichostatin A represses estrogen receptor β-dependent transcription and promotes proteasomal degradation of cyclin D1 in human breast carcinoma cell lines Clin Cancer Res 10 8094 8104
    • (2004) Clin Cancer Res , vol.10 , pp. 8094-8104
    • Alao, J.P.1    Lam, E.W.2    Ali, S.3
  • 71
    • 33644836891 scopus 로고    scopus 로고
    • Histone deacetylase inhibitor, trichostatin a induces ubiquitin-dependent cyclin D1 degradation in MCF-7 breast cancer cells
    • JP Alao AV Stavropoulou EW Lam RC Coombes DM Vigushin 2006 Histone deacetylase inhibitor, trichostatin A induces ubiquitin-dependent cyclin D1 degradation in MCF-7 breast cancer cells Mol Cancer 5 8 8
    • (2006) Mol Cancer , vol.5 , pp. 8-8
    • Alao, J.P.1    Stavropoulou, A.V.2    Lam, E.W.3    Coombes, R.C.4    Vigushin, D.M.5
  • 72
    • 5144222440 scopus 로고    scopus 로고
    • WAF1/CIP1 expression through downregulation of c-myc and release of the repression of c-myc from the promoter in human cervical cancer cells
    • WAF1/CIP1 expression through downregulation of c-myc and release of the repression of c-myc from the promoter in human cervical cancer cells Biochem Biophys Res Commun 324 860 867
    • (2004) Biochem Biophys Res Commun , vol.324 , pp. 860-867
    • Li, H.1    Wu, X.2
  • 73
    • 0034737290 scopus 로고    scopus 로고
    • Exit from G1 and S phase of the cell cycle is regulated by repressor complexes containing HDAC-Rb-hSWI/SNF and Rb-hSWI/SNF
    • HS Zhang M Gavin A Dahiya 2000 Exit from G1 and S phase of the cell cycle is regulated by repressor complexes containing HDAC-Rb-hSWI/SNF and Rb-hSWI/SNF Cell 101 79 89
    • (2000) Cell , vol.101 , pp. 79-89
    • Zhang, H.S.1    Gavin, M.2    Dahiya, A.3
  • 74
    • 0037377060 scopus 로고    scopus 로고
    • Ubiquitination, phosphorylation and acetyla-tion: The molecular basis for p53 regulation
    • CL Brooks W Gu 2003 Ubiquitination, phosphorylation and acetyla-tion: the molecular basis for p53 regulation Curr Opin Cell Biol 15 164 171
    • (2003) Curr Opin Cell Biol , vol.15 , pp. 164-171
    • Brooks, C.L.1    Gu, W.2
  • 75
    • 1642490813 scopus 로고    scopus 로고
    • Histone deacetylase inhibitor LAQ824 down-regulates Her-2 and sensitizes human breast cancer cells to trastuzumab, taxotere, gemcitabine, and epothilone B
    • L Fuino P Bali S Wittmann 2003 Histone deacetylase inhibitor LAQ824 down-regulates Her-2 and sensitizes human breast cancer cells to trastuzumab, taxotere, gemcitabine, and epothilone B Mol Cancer Ther 2 971 984
    • (2003) Mol Cancer Ther , vol.2 , pp. 971-984
    • Fuino, L.1    Bali, P.2    Wittmann, S.3
  • 76
    • 0043016178 scopus 로고    scopus 로고
    • Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells
    • R Nimmanapalli L Fuino P Bali 2003 Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells Cancer. Res. 63 5126 5135
    • (2003) Cancer. Res. , vol.63 , pp. 5126-5135
    • Nimmanapalli, R.1    Fuino, L.2    Bali, P.3
  • 77
    • 33748427812 scopus 로고    scopus 로고
    • Histone deacetylase inhibitors (HDI) cause DNA damage in leukemia cells: A mechanism for leukemia-specific HDI-dependent apoptosis?
    • TJ Gaymes RA Padua M Pla 2006 Histone deacetylase inhibitors (HDI) cause DNA damage in leukemia cells: a mechanism for leukemia-specific HDI-dependent apoptosis? Mol Cancer Res 4 563 573
    • (2006) Mol Cancer Res , vol.4 , pp. 563-573
    • Gaymes, T.J.1    Padua, R.A.2    Pla, M.3
  • 78
    • 20044390016 scopus 로고    scopus 로고
    • Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors
    • JS Ungerstedt Y Sowa WS Xu 2005 Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors Proc NatlAcad Sci USA 102 673 678
    • (2005) Proc NatlAcad Sci USA , vol.102 , pp. 673-678
    • Ungerstedt, J.S.1    Sowa, Y.2    Xu, W.S.3
  • 79
    • 0041347519 scopus 로고    scopus 로고
    • Histone deacetylase inhibitors in cancer therapy: Is transcription the primary target?
    • RW Johnstone JD Licht 2003 Histone deacetylase inhibitors in cancer therapy: is transcription the primary target? Cancer Cell 4 13 18
    • (2003) Cancer Cell , vol.4 , pp. 13-18
    • Johnstone, R.W.1    Licht, J.D.2
  • 80
    • 25144487124 scopus 로고    scopus 로고
    • Mechanisms of selective anticancer action of histone deacetylase inhibitors
    • A Insinga S Minucci PG Pelicci 2005 Mechanisms of selective anticancer action of histone deacetylase inhibitors Cell Cycle 4 741 743
    • (2005) Cell Cycle , vol.4 , pp. 741-743
    • Insinga, A.1    Minucci, S.2    Pelicci, P.G.3
  • 81
    • 33845209109 scopus 로고    scopus 로고
    • Histone deacetylase inhibitors and paclitaxel cause synergistic effects on apoptosis and micro-tubule stabilization in papillary serous endometrial cancer cells
    • SC Dowdy S Jiang XC Zhou 2006 Histone deacetylase inhibitors and paclitaxel cause synergistic effects on apoptosis and micro-tubule stabilization in papillary serous endometrial cancer cells Mol Cancer Ther 5 2767 2776
    • (2006) Mol Cancer Ther , vol.5 , pp. 2767-2776
    • Dowdy, S.C.1    Jiang, S.2    Zhou, X.C.3
  • 82
    • 33749031527 scopus 로고    scopus 로고
    • Synergistic effects of valproic acid and mitomycin C in adenocarcinoma cell lines and fresh tumor cells of patients with colon cancer
    • I Friedmann A Atmaca KU Chow E Jager E eidmann 2006 Synergistic effects of valproic acid and mitomycin C in adenocarcinoma cell lines and fresh tumor cells of patients with colon cancer J Chemother 18 415 420
    • (2006) J Chemother , vol.18 , pp. 415-420
    • Friedmann, I.1    Atmaca, A.2    Chow, K.U.3    Jager, E.4    Eidmann, E.5
  • 83
    • 0033615547 scopus 로고    scopus 로고
    • Sensing of ionizing radiation-induced DNA damage by ATM through interaction with histone deacetylase
    • GD Kim YH Choi A Dimtchev SJ Jeong A Dritschilo M Jung 1999 Sensing of ionizing radiation-induced DNA damage by ATM through interaction with histone deacetylase J Biol Chem 274 31127 31130
    • (1999) J Biol Chem , vol.274 , pp. 31127-31130
    • Kim, G.D.1    Choi, Y.H.2    Dimtchev, A.3    Jeong, S.J.4    Dritschilo, A.5    Jung, M.6
  • 84
    • 0032948005 scopus 로고    scopus 로고
    • Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer
    • EE Cameron KE Bachman S Myohanen JG Herman SB Baylin 1999 Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer Nat Genet 21 103 107
    • (1999) Nat Genet , vol.21 , pp. 103-107
    • Cameron, E.E.1    Bachman, K.E.2    Myohanen, S.3    Herman, J.G.4    Baylin, S.B.5
  • 85
    • 33747874802 scopus 로고    scopus 로고
    • Histone deacetylase inhibitor trichostatin a and proteasome inhibitor PS-341 synergistically induce apoptosis in pancreatic cancer cells
    • J Bai A Demirjian J Sui W Marasco MP Callery 2006 Histone deacetylase inhibitor trichostatin A and proteasome inhibitor PS-341 synergistically induce apoptosis in pancreatic cancer cells Biochem Biophys Res Commun 348 1245 1253
    • (2006) Biochem Biophys Res Commun , vol.348 , pp. 1245-1253
    • Bai, J.1    Demirjian, A.2    Sui, J.3    Marasco, W.4    Callery, M.P.5
  • 86
    • 4444309863 scopus 로고    scopus 로고
    • Treatment of myelodys-plastic syndromes with valproic acid alone or in combination withall-trans retinoic acid
    • A Kuendgen C Strupp M Aivado 2004 Treatment of myelodys-plastic syndromes with valproic acid alone or in combination withall-trans retinoic acid Blood 104 1266 1269
    • (2004) Blood , vol.104 , pp. 1266-1269
    • Kuendgen, A.1    Strupp, C.2    Aivado, M.3
  • 87
    • 33750530675 scopus 로고    scopus 로고
    • Phase 1/2 study of the combination of 5-aza-2-deoxycytidine with valproic acid in patients with leukemia
    • G Garcia-Manero HM Kantarjian B Sanchez-Gonzalez 2006 Phase 1/2 study of the combination of 5-aza-2-deoxycytidine with valproic acid in patients with leukemia Blood 108 3271 3279
    • (2006) Blood , vol.108 , pp. 3271-3279
    • Garcia-Manero, G.1    Kantarjian, H.M.2    Sanchez-Gonzalez, B.3
  • 88
    • 0037105374 scopus 로고    scopus 로고
    • Bone marrow transplantation from HLA-identical siblings as treatment for myelodysplasia
    • J Sierra WS Perez C Rozman 2002 Bone marrow transplantation from HLA-identical siblings as treatment for myelodysplasia Blood 100 1997 2004
    • (2002) Blood , vol.100 , pp. 1997-2004
    • Sierra, J.1    Perez, W.S.2    Rozman, C.3
  • 89
    • 22344451414 scopus 로고    scopus 로고
    • Improved outcome for peripheral blood stem cell transplantation for advanced primary myelodysplastic syndrome
    • SR Solomon BN Savani R Childs 2005 Improved outcome for peripheral blood stem cell transplantation for advanced primary myelodysplastic syndrome Biol Blood Marrow Transplant 11 619 626
    • (2005) Biol Blood Marrow Transplant , vol.11 , pp. 619-626
    • Solomon, S.R.1    Savani, B.N.2    Childs, R.3
  • 90
    • 33846953453 scopus 로고    scopus 로고
    • Myelodysplastic syndromes in patients younger than age 50
    • A Kuendgen C Strupp M Aivado 2006 Myelodysplastic syndromes in patients younger than age 50 J Clin Oncol 24 5358 5365
    • (2006) J Clin Oncol , vol.24 , pp. 5358-5365
    • Kuendgen, A.1    Strupp, C.2    Aivado, M.3
  • 91
    • 2142725956 scopus 로고    scopus 로고
    • Combined stratification of refractory anemia according to both WHO and IPSS criteria has a prognostic impact and improves identification of patients who may benefit from stem cell transplantation
    • J Cermak A Vitek K Michalova 2004 Combined stratification of refractory anemia according to both WHO and IPSS criteria has a prognostic impact and improves identification of patients who may benefit from stem cell transplantation Leuk Res 28 551 557
    • (2004) Leuk Res , vol.28 , pp. 551-557
    • Cermak, J.1    Vitek, A.2    Michalova, K.3
  • 93
    • 33746661102 scopus 로고    scopus 로고
    • Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes
    • R Martino S Iacobelli R Brand 2006 Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes Blood 108 836 846
    • (2006) Blood , vol.108 , pp. 836-846
    • Martino, R.1    Iacobelli, S.2    Brand, R.3
  • 94
    • 0030729822 scopus 로고    scopus 로고
    • Autologous bone marrow transplantation for patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia following MDS: Chronic and Acute Leukemia Working Parties of the European Group for Blood and Marrow Transplantation
    • T De Witte A Van Biezen J Hermans 1997 Autologous bone marrow transplantation for patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia following MDS: Chronic and Acute Leukemia Working Parties of the European Group for Blood and Marrow Transplantation Blood 90 3853 3857
    • (1997) Blood , vol.90 , pp. 3853-3857
    • De Witte, T.1    Van Biezen, A.2    Hermans, J.3
  • 95
    • 33644553459 scopus 로고    scopus 로고
    • Long-term follow-up results of the combination of topotecan and cytarabine and other intensive chemotherapy regimens in myelodysplastic syndrome
    • H Kantarjian M Beran J Cortes 2006 Long-term follow-up results of the combination of topotecan and cytarabine and other intensive chemotherapy regimens in myelodysplastic syndrome Cancer 106 1099 1109
    • (2006) Cancer , vol.106 , pp. 1099-1109
    • Kantarjian, H.1    Beran, M.2    Cortes, J.3
  • 96
    • 0032884937 scopus 로고    scopus 로고
    • Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukemia
    • M Beran E Estey S O'Brien 1999 Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukemia J Clin Oncol 17 2819 2830
    • (1999) J Clin Oncol , vol.17 , pp. 2819-2830
    • Beran, M.1    Estey, E.2    O'Brien, S.3
  • 97
    • 0026481129 scopus 로고
    • The evaluation of low-dose cytarabine in the treatment of myelodysplastic syndromes: A phase-III intergroup study
    • KB Miller K Kim FS Morrison 1992 The evaluation of low-dose cytarabine in the treatment of myelodysplastic syndromes: a phase-III intergroup study Ann Hematol 65 162 168
    • (1992) Ann Hematol , vol.65 , pp. 162-168
    • Miller, K.B.1    Kim, K.2    Morrison, F.S.3
  • 98
    • 27644562303 scopus 로고    scopus 로고
    • Low-dose cytosine ara-binoside (LD-AraC) vs LD-AraC plus granulocyte/macrophage colony stimulating factor vs LD-AraC plus interleukin-3 for myelodysplastic syndrome patients with a high risk of developing acute leukemia: Final results of a randomized phase III study (06903) of the EORTC Leukemia Cooperative Group
    • H Zwierzina S Suciu J Loeffler-Ragg 2005 Low-dose cytosine ara-binoside (LD-AraC) vs LD-AraC plus granulocyte/macrophage colony stimulating factor vs LD-AraC plus interleukin-3 for myelodysplastic syndrome patients with a high risk of developing acute leukemia: final results of a randomized phase III study (06903) of the EORTC Leukemia Cooperative Group Leukemia 19 1929 1933
    • (2005) Leukemia , vol.19 , pp. 1929-1933
    • Zwierzina, H.1    Suciu, S.2    Loeffler-Ragg, J.3
  • 99
    • 23844431694 scopus 로고    scopus 로고
    • Lenalidomide (Revlimid, CC-5013) in myelodysplastic syndromes: Is it any good?
    • MA Sekeres A List 2005 Lenalidomide (Revlimid, CC-5013) in myelodysplastic syndromes: is it any good? Curr Hematol Rep 4 182 185
    • (2005) Curr Hematol Rep , vol.4 , pp. 182-185
    • Sekeres, M.A.1    List, A.2
  • 100
    • 2142712474 scopus 로고    scopus 로고
    • Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome
    • R Kurzrock M Albitar JE Cortes 2004 Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome J Clin Oncol 22 1287 1292
    • (2004) J Clin Oncol , vol.22 , pp. 1287-1292
    • Kurzrock, R.1    Albitar, M.2    Cortes, J.E.3
  • 101
    • 10744227474 scopus 로고    scopus 로고
    • Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: Clinical and biologic activities in the phase 1 setting
    • R Kurzrock HM Kantarjian JE Cortes 2003 Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: clinical and biologic activities in the phase 1 setting Blood 102 4527 4534
    • (2003) Blood , vol.102 , pp. 4527-4534
    • Kurzrock, R.1    Kantarjian, H.M.2    Cortes, J.E.3
  • 102
    • 35148834657 scopus 로고    scopus 로고
    • Clofarabine is active in myelodysplastic syndrome (MDS)
    • [abstract]. Abstract 2660.
    • Faderl S, Gandhi V, O'Brien S, et al. Clofarabine is active in myelodysplastic syndrome (MDS) [abstract].Blood 2006;108. Abstract 2660.
    • (2006) Blood , vol.108
    • Faderl, S.1    Gandhi, V.2    O'Brien, S.3
  • 103
    • 4544267031 scopus 로고    scopus 로고
    • The role of angiogenesis in the biology and therapy of myelodysplastic syndromes
    • A Aguayo 2004 The role of angiogenesis in the biology and therapy of myelodysplastic syndromes Curr Hematol Rep 3 184 191
    • (2004) Curr Hematol Rep , vol.3 , pp. 184-191
    • Aguayo, A.1
  • 104
    • 0036172446 scopus 로고    scopus 로고
    • Soluble TNF receptor fusion protein (etanercept) for the treatment of myelodysplastic syndrome: A pilot study
    • HJ Deeg J Gotlib C Beckham 2002 Soluble TNF receptor fusion protein (etanercept) for the treatment of myelodysplastic syndrome: a pilot study Leukemia 16 162 164
    • (2002) Leukemia , vol.16 , pp. 162-164
    • Deeg, H.J.1    Gotlib, J.2    Beckham, C.3
  • 105
    • 33745002275 scopus 로고    scopus 로고
    • Phase II multicenter study of arsenic trioxide in patients with myelodysplastic syndromes
    • GJ Schiller J Slack JD Hainsworth 2006 Phase II multicenter study of arsenic trioxide in patients with myelodysplastic syndromes J Clin Oncol 24 2456 2464
    • (2006) J Clin Oncol , vol.24 , pp. 2456-2464
    • Schiller, G.J.1    Slack, J.2    Hainsworth, J.D.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.